The first diagnostic test to classify cancers by differences in microRNAs–small pieces of RNA that regulate genes–will soon be on the market. The test distinguishes two types of lung cancer and should help doctors tailor treatments to their patients’ needs. Scientists say that tests based on microRNA profiles could prove more sensitive and reliable than existing methods, whose accuracy depends heavily on the judgment of the people analyzing them.
Product: MicroRNA test for lung cancer
Cost: Comparable to that of other molecular tests for cancer, which are priced at around $3,000 to $3,500
Company: Rosetta Genomics
Subscribe to Continue Reading
Uh oh–you've read all five of your free articles for this month.
Insider Online Only
$19.95/yr US PRICE
The Map of the Human Brain Is Finally Getting More Useful
Human Connectome Project neuroscientists have created a program to make individualized brain maps.
Gene Therapy Trial Wrenches Families as One Child’s Death Saves Another
New DNA fix stops brain-destroying terminal illness, but only if it’s given early enough.
The Long Road to Obama’s Cancer Moonshot
We’ve tried to cure cancer before. Will this time be different?